GlaxoSmithKline PLC (GSK) - Total Liabilities
Based on the latest financial reports, GlaxoSmithKline PLC (GSK) has total liabilities worth GBX45.59 Billion GBX (≈ $5.55 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore GSK net asset momentum to track the company's year-over-year net asset growth rate.
GlaxoSmithKline PLC - Total Liabilities Trend (1986–2024)
This chart illustrates how GlaxoSmithKline PLC's total liabilities have evolved over time, based on quarterly financial data. See cash generation quality of GlaxoSmithKline PLC to measure how efficiently the company converts operating cash flow to free cash.
GlaxoSmithKline PLC Competitors by Total Liabilities
The table below lists competitors of GlaxoSmithKline PLC ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Viet Capital Securities JSC
VN:VCI
|
Vietnam | ₫19.78 Trillion |
|
Hyundai Development Co
KO:294870
|
Korea | ₩4.91 Trillion |
|
Pet Valu Holdings Ltd
TO:PET
|
Canada | CA$963.90 Million |
|
Gr. Sarantis S.A.
AT:SAR
|
Greece | €232.08 Million |
|
China Hi-Tech Group Co Ltd
SHG:600730
|
China | CN¥231.83 Million |
|
Zhejiang Chenfeng Science and Technology Co Ltd Class A
SHG:603685
|
China | CN¥1.85 Billion |
|
United Renewable Energy Co Ltd
TW:3576
|
Taiwan | NT$13.63 Billion |
|
Troax Group AB
ST:TROAX
|
Sweden | Skr250.50 Million |
Liability Composition Analysis (1986–2024)
This chart breaks down GlaxoSmithKline PLC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see GSK market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.84 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.82 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.74 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how GlaxoSmithKline PLC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for GlaxoSmithKline PLC (1986–2024)
The table below shows the annual total liabilities of GlaxoSmithKline PLC from 1986 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | GBX46.38 Billion ≈ $5.64 Million |
+0.36% |
| 2023-12-31 | GBX46.21 Billion ≈ $5.62 Million |
-7.67% |
| 2022-12-31 | GBX50.05 Billion ≈ $6.09 Million |
-13.35% |
| 2021-12-31 | GBX57.76 Billion ≈ $7.03 Million |
-3.12% |
| 2020-12-31 | GBX59.62 Billion ≈ $7.25 Million |
-2.79% |
| 2019-12-31 | GBX61.34 Billion ≈ $7.46 Million |
+12.76% |
| 2018-12-31 | GBX54.39 Billion ≈ $6.62 Million |
+2.84% |
| 2017-12-31 | GBX52.89 Billion ≈ $6.44 Million |
-2.27% |
| 2016-12-31 | GBX54.12 Billion ≈ $6.58 Million |
+21.43% |
| 2015-12-31 | GBX44.57 Billion ≈ $5.42 Million |
+24.79% |
| 2014-12-31 | GBX35.72 Billion ≈ $4.35 Million |
+4.20% |
| 2013-12-31 | GBX34.27 Billion ≈ $4.17 Million |
-1.31% |
| 2012-12-31 | GBX34.73 Billion ≈ $4.23 Million |
+7.67% |
| 2011-12-31 | GBX32.25 Billion ≈ $3.92 Million |
-0.17% |
| 2010-12-31 | GBX32.31 Billion ≈ $3.93 Million |
+0.58% |
| 2009-12-31 | GBX32.12 Billion ≈ $3.91 Million |
+3.36% |
| 2008-12-31 | GBX31.07 Billion ≈ $3.78 Million |
+47.32% |
| 2007-12-31 | GBX21.09 Billion ≈ $2.57 Million |
+32.62% |
| 2006-12-31 | GBX15.90 Billion ≈ $1.94 Million |
-18.97% |
| 2005-12-31 | GBX19.63 Billion ≈ $2.39 Million |
+15.41% |
| 2004-12-31 | GBX17.01 Billion ≈ $2.07 Million |
+10.46% |
| 2003-12-31 | GBX15.40 Billion ≈ $1.87 Million |
+3.06% |
| 2002-12-31 | GBX14.94 Billion ≈ $1.82 Million |
+10.10% |
| 2001-12-31 | GBX13.57 Billion ≈ $1.65 Million |
+7.39% |
| 2000-12-31 | GBX12.63 Billion ≈ $1.54 Million |
+74.66% |
| 1999-12-31 | GBX7.23 Billion ≈ $880.17K |
+9.97% |
| 1998-12-31 | GBX6.58 Billion ≈ $800.35K |
+0.47% |
| 1997-12-31 | GBX6.55 Billion ≈ $796.58K |
-7.10% |
| 1996-12-31 | GBX7.05 Billion ≈ $857.42K |
-15.30% |
| 1995-12-31 | GBX8.32 Billion ≈ $1.01 Million |
+10.53% |
| 1995-06-30 | GBX7.53 Billion ≈ $915.87K |
+174.92% |
| 1994-06-30 | GBX2.74 Billion ≈ $333.14K |
-2.25% |
| 1993-06-30 | GBX2.80 Billion ≈ $340.80K |
+37.10% |
| 1992-06-30 | GBX2.04 Billion ≈ $248.57K |
-17.02% |
| 1991-06-30 | GBX2.46 Billion ≈ $299.55K |
+45.94% |
| 1990-06-30 | GBX1.69 Billion ≈ $205.26K |
+45.93% |
| 1989-06-30 | GBX1.16 Billion ≈ $140.65K |
+8.65% |
| 1988-06-30 | GBX1.06 Billion ≈ $129.46K |
+19.02% |
| 1987-06-30 | GBX894.00 Million ≈ $108.77K |
+27.17% |
| 1986-06-30 | GBX703.00 Million ≈ $85.53K |
-- |
About GlaxoSmithKline PLC
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, infl… Read more